Takeda Pharmaceutical Co. $TAK Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC reduced its holdings in Takeda Pharmaceutical Co. (NYSE:TAK) by 31.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 76,483 shares of the company’s stock after selling 35,614 shares during the period. Corient Private Wealth LLC’s holdings in Takeda Pharmaceutical were worth $1,192,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Pure Financial Advisors LLC acquired a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at approximately $164,000. SHP Wealth Management purchased a new position in Takeda Pharmaceutical during the fourth quarter worth approximately $42,000. Keenan LLC acquired a new position in Takeda Pharmaceutical during the fourth quarter worth $273,000. SG Trading Solutions LLC acquired a new position in Takeda Pharmaceutical during the fourth quarter worth $682,000. Finally, Compound Planning Inc. grew its holdings in Takeda Pharmaceutical by 8.3% in the 4th quarter. Compound Planning Inc. now owns 45,673 shares of the company’s stock valued at $712,000 after buying an additional 3,515 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

TAK stock opened at $15.96 on Thursday. The business’s 50-day moving average is $16.09 and its two-hundred day moving average is $16.84. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.09 and a quick ratio of 0.60. The firm has a market capitalization of $50.78 billion, a P/E ratio of 40.91 and a beta of -0.07. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. The firm had revenue of $6.90 billion for the quarter. Analysts anticipate that Takeda Pharmaceutical Co. will post 0.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TAK. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Sunday. Finally, Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.